Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Jorge J CastilloJohn N AllanTanya SiddiqiRanjana H AdvaniKirsten MeidCarly LeventoffTimothy P WhiteCatherine A FlynnShayna R SarosiekAndrew R BranaganMaria G DemosMaria L GuerreraAmanda KofidesXia LiuManit MunshiNicholas TsakmaklisLian XuGuang YangChristopher J PattersonZachary R HunterMatthew S DavidsRichard R FurmanSteven P TreonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Venetoclax is safe and highly active in patients with previously treated WM, including those who previously received BTKis. CXCR4 mutation status did not affect treatment response.